CryoPort (NASDAQ:CYRX) Issues Earnings Results

Key Points

• CryoPort reported a quarterly loss of ($0.29) earnings per share, falling short of the consensus estimate of ($0.20) by $0.09, and had a negative net margin of 50.15%.
• The company's stock price fell to $6.74, while institutional investors collectively own 92.90% of its shares, indicating strong institutional interest.
• Various analysts have issued ratings, with target prices ranging from $7.00 to $13.00, reflecting a generally optimistic outlook despite recent price reductions.

CryoPort (NASDAQ:CYRX - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09), Zacks reports. CryoPort had a net margin of 37.21% and a negative return on equity of 10.48%. The business had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort updated its FY 2025 guidance to EPS.

CryoPort Trading Down 7.8%

Shares of NASDAQ CYRX traded down $0.64 during midday trading on Friday, hitting $7.56. The company's stock had a trading volume of 981,876 shares, compared to its average volume of 974,076. CryoPort has a 12-month low of $4.58 and a 12-month high of $9.66. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51. The firm has a market cap of $379.06 million, a P/E ratio of 5.68 and a beta of 1.88. The business's 50 day moving average is $7.20 and its two-hundred day moving average is $6.59.

Insiders Place Their Bets

In other CryoPort news, Director Ramkumar Mandalam sold 40,728 shares of the stock in a transaction on Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total value of $294,870.72. Following the sale, the director owned 92,328 shares in the company, valued at $668,454.72. This trade represents a 30.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 151,304 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $6.81, for a total transaction of $1,030,380.24. Following the sale, the chief executive officer directly owned 912,419 shares of the company's stock, valued at $6,213,573.39. This represents a 14.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 490,447 shares of company stock worth $3,337,198 in the last 90 days. 10.00% of the stock is owned by insiders.

Hedge Funds Weigh In On CryoPort

An institutional investor recently bought a new position in CryoPort stock. Creative Planning acquired a new position in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,880 shares of the company's stock, valued at approximately $96,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CYRX. Stephens initiated coverage on shares of CryoPort in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 target price for the company. KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price objective for the company in a research note on Wednesday. Leerink Partnrs upgraded shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price target on shares of CryoPort in a report on Thursday, May 8th. Finally, BTIG Research reduced their price objective on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, July 7th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $12.00.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.